ICCC Q2 2023 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-8.5% YoY

Gross Profit

$1M29.5% margin

Operating Income

-$1M-36.9% margin

Net Income

-$1M-39.1% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

+2.5%

Cash Flow

Operating Cash Flow

-$681,426

Free Cash Flow

-$1M

Stock-Based Comp.

$75,657

Balance Sheet

Total Assets

$44M

Total Liabilities

$17M

Stockholders' Equity

$27M

Cash & Equivalents

$1M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$4M	-8.5%
Gross Profit	$1M	$2M	-38.9%
Operating Income	-$1M	-$619,007	-110.7%
Net Income	-$1M	-$684,148	-101.7%